Pollom Erqi L, Chin Alexander L, Diehn Maximilian, Loo Billy W, Chang Daniel T
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA.
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA.
Semin Radiat Oncol. 2017 Jul;27(3):197-208. doi: 10.1016/j.semradonc.2017.02.001. Epub 2017 Feb 20.
Although stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy has become an established standard of care for the treatment of a variety of malignancies, our understanding of normal tissue dose tolerance with extreme hypofractionation remains immature. Since Timmerman initially proposed normal tissue dose constraints for SBRT in the 2008 issue of Seminars of Radiation Oncology, experience with SBRT has grown, and more long-term clinical outcome data have been reported. This article reviews the modern toxicity literature and provides updated clinically practical and useful recommendations of SBRT dose constraints for extracranial sites. We focus on the major organs of the thoracic and upper abdomen, specifically the liver and the lung.
尽管立体定向体部放疗（SBRT）或立体定向消融放疗已成为治疗多种恶性肿瘤的既定标准治疗方法，但我们对超分割放疗时正常组织剂量耐受性的理解仍不成熟。自蒂默曼在2008年《放射肿瘤学研讨会》上首次提出SBRT的正常组织剂量限制以来，SBRT的经验不断积累，更多长期临床结果数据也已报道。本文回顾了现代毒性文献，并提供了针对颅外部位SBRT剂量限制的最新临床实用且有用的建议。我们重点关注胸部和上腹部的主要器官，特别是肝脏和肺。
